The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRDN | +32.95% | +82.32% | +12.75% | -84% |
| S&P | +13.19% | +87.83% | +13.42% | +188% |
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $70.57M | 81958.1% |
| Gross Profit | $70.26M | 28895.1% |
| Gross Margin | 99.56% | 383.3% |
| Market Cap | $1.76B | 1.4% |
| Market Cap / Employee | $12.32M | 0.0% |
| Employees | 143 | 49.0% |
| Net Income | -$34.60M | 54.9% |
| EBITDA | -$39.70M | 52.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $169.65M | -15.3% |
| Accounts Receivable | $70.00M | 499900.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $23.09M | 1.8% |
| Short Term Debt | $0.73M | 23.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.53% | 4.2% |
| Return On Invested Capital | -49.63% | 35.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$84.74M | -24.6% |
| Operating Free Cash Flow | -$84.61M | -25.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.93 | 2.26 | 2.74 | 5.40 | 71.63% |
| Price to Sales | 5081.45 | 3630.86 | 3739.92 | 24.93 | -99.50% |
| Price to Tangible Book Value | 2.93 | 2.26 | 2.74 | 5.40 | 71.63% |
| Enterprise Value to EBITDA | -11.78 | -7.18 | -7.41 | -37.45 | 221.00% |
| Return on Equity | -45.8% | -49.4% | -63.0% | -47.4% | -8.63% |
| Total Debt | $23.10M | $23.11M | $23.04M | $23.82M | 2.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
